A Phase 2 interventional study of Ruxolitinib cream and Vehicle in Hand Eczema, sponsored by Incyte Corporation. Completed at 36 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Eczema by Incyte Corporation — 2 open to participants now, 2 under way, none of them phase 3. Eczema · Incyte Corporation.
Among the 10 studies in Eczema by Incyte Corporation, this one is one of 5 that started in 2023, is one of 2 in phase 2, and was the 7th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →2 of the 10 studies in Eczema by Incyte Corporation are open now, in 1 country. Recruiting first, the newest first:
Incyte Corporation · Sites in United States
Ages 15–50 · Women only
Incyte Corporation · Sites in United States
Ages 14+ · Women only
By country, each count listing its studies:
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is above the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 214 across the 8 interventional studies, 3,290 across the 2 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Eczema by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06627335Incyte CorporationAn Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis | 2027-08-15 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Eczema by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
Drug: Ruxolitinib cream
Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
Drug: Vehicle
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Also known as: INCB18424 cream
Vehicle cream is a topical formulation applied as a thin film to affected areas.
Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16
The Investigator's Global Assessment-Chronic Hand Eczema (IGA-CHE) is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.
Time frame: Baseline; Week 16
Percentage of Participants Achieving ITCH4 Response at Weeks 4 and 16
ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).
Time frame: Baseline; Weeks 4 and 16
Percentage of Participants Achieving ITCH4 Response at Day 3 and Week 1 (Day 7)
ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).
Time frame: Baseline; Day 3; Week 1 (Day 7)
Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Each Post-Baseline Visit
The IGA-CHE is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.
Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 24, and 32
Change From Baseline in CHE-related Itch NRS Score at Each Post-Baseline Visit
The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 1-32
Time to ≥4-point Improvement From Baseline in CHE-related Itch NRS Score
ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).
Time frame: Baseline; up to Week 32
Change From Baseline in CHE-related Pain NRS Score at Each Post-Baseline Visit
The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Weeks 1-32
Percentage of Participants Achieving ≥2-point Improvement in CHE-related Skin Pain NRS Score From Baseline to Week 16
The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).
Time frame: Baseline; up to Week 16
Time to ≥2-point Improvement From Baseline in CHE-related Skin Pain NRS Score
The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).
Time frame: Baseline; up to Week 32
Percentage Change in Hand Eczema Severity Index (HECSI) Score From Baseline to Week 16
The HECSI divides the hand into 5 areas for assessment (fingertips, fingers \[except the tips\], palms, back of hands, and wrists). Each of the 5 areas of the hand are assessed separately for erythema, induration/papulation, vesicles, fissuring, scaling, and edema using the following scale: 0, no skin changes; 1, mild disease; 2, moderate disease; and 3, severe disease. To determine the HECSI score, the affected area for each location (total of both hands) is given a score from 0 to 4 (0, 0%; 1, 1%-25%; 2, 26%-50%; 3, 51%-75%; and 4, 76%-100%) based on the extent of clinical symptoms. Finally, the score given for the extent at each location is multiplied by the total sum of the intensity of each clinical feature to calculate the total HECSI score, varying from 0 to a maximum severity score of 360 points. Percentage change was calculated as the (\[post-Baseline value minus the Baseline value\]/\[Baseline value\]) \* 100.
Time frame: Baseline; up to Week 16
Patient Global Impression of Change (PGIC) Score at Each Post-Baseline Visit
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement of CHE. Participants were asked to select 1 response from the response options that best described the overall change in their CHE since they started study treatment: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse, and 7, very much worse.
Time frame: Baseline; up to Week 32
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Weeks 2, 4, 8, 12, 16, 24, and 32
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. The questionnaire was analyzed under 6 subscales as follows: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); and treatment (Question 10). Scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0 (Question 7: "Prevented work or studying" = Yes = 3). The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.
Time frame: Baseline; up to Week 32
Number of Participants With the Indicated EQ-5D-5L Dimension Scores at Weeks 2, 4, 8, 12, 16, 24, and 32
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score).
Time frame: Baseline; up to Week 32
Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Score at Weeks 2, 4, 8, 12, 16, 24, and 32
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 32
Change From Baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) Total Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up
The QOLHEQ is a validated disease-specific instrument to assess disease-specific health-related quality of life in participants suffering from CHE over the past 7 days. It consists of 30 items that are summarized according to impairments for 4 subscales: symptoms, emotions, limitations in functioning, and treatment and prevention. Each item is scored on a scale of never, rarely, sometimes, often, and all the time. The overall score is calculated by summing all items and ranges from 0 to 117. Higher scores indicate a greater impact on quality of life. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 36
Change From Baseline in Work Productivity and Activity Impairment Questionnaire v2.0 in Chronic Hand Dermatitis (WPAI-ChHD) Score at Weeks 2, 4, 8, 12, 16, 24, 32, and Follow-up
The WPAI-ChHD questionnaire is a patient-reported quantitative assessment of the amount of absenteeism (measured as percentage of work time missed \[PWTM\] due to CHE), presentism, and daily activity impairment (percentage of impairment while working \[PIWW\] due to CHE, percentage of overall work impairment \[POWI\] due to CHE, percentage of activity impairment \[PAI\] due to CHE) attributable to a specific health problem. The WPAI-ChHD is a 6-item questionnaire used to assess the impact of chronic hand dermatitis (ChHD, the same as CHE in this context) on job performance and productivity in the last 7 days. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Scores range from 0% (no impairment) to 100% (complete impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 36
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) in the DBVC Period
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.
Time frame: up to Week 16
Number of Participants With Any ≥Grade 3 TEAE in the DBVC Period
A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to Week 16
Number of Participants With Any TEAE in the OLE Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.
Time frame: up to Week 36
Number of Participants With Any ≥Grade 3 TEAE in the OLE Period
A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to Week 36
Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the DBVC Period
The investigator determined whether a change was clinically meaningful.
Time frame: up to Week 16
Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the OLE Period
The investigator determined whether a change was clinically meaningful.
Time frame: up to Week 36
| Milestone | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Started | 94 | 92 |
| Completed | 84 | 77 |
| Not completed | 10 | 15 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Withdrawal by subject | 4 | 11 |
| Milestone | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Started | 84 | 77 |
| Completed | 76 | 71 |
| Not completed | 8 | 6 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 4 |
The Investigator's Global Assessment-Chronic Hand Eczema (IGA-CHE) is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.
| percentage of participants | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16 | 53.2 (42.6 to 63.6) | 10.9 (5.3 to 19.1) |
ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).
| percentage of participants | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Week 4 | 46.7 (36.3 to 57.4) | 17.6 (10.4 to 27.0) |
| Week 16 | 52.2 (41.5 to 62.7) | 23.1 (14.9 to 33.1) |
ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).
| percentage of participants | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Day 3 | 12.9 (6.6 to 22.0) | 6.0 (2.0 to 13.5) |
| Week 1 (Day 7) | 28.0 (18.7 to 39.1) | 9.5 (4.2 to 17.9) |
The IGA-CHE is an instrument used to rate the severity of the participant's global CHE and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (1, almost clear; 2, mild eczema; 3, moderate eczema). IGA-CHE TS is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from Baseline.
| percentage of participants | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Week 2 | 22.5 (14.3 to 32.6) | 1.2 (0.0 to 6.3) |
| Week 4 | 37.8 (27.8 to 48.6) | 4.8 (1.3 to 11.7) |
| Week 8 | 44.3 (33.7 to 55.3) | 3.8 (0.8 to 10.6) |
| Week 12 | 52.9 (41.9 to 63.7) | 14.1 (7.3 to 23.8) |
| Week 16 | 58.1 (47.0 to 68.7) | 12.8 (6.3 to 22.3) |
| Week 24 | 51.2 (39.9 to 62.4) | 51.4 (39.4 to 63.1) |
| Week 32 | 52.6 (40.9 to 64.0) | 54.8 (42.7 to 66.5) |
The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Baseline | 6.68 ± 1.619 | 6.63 ± 1.592 |
| Change from Baseline at Week 2 | -3.03 ± 2.346 | -1.34 ± 1.725 |
| Change from Baseline at Week 4 | -3.88 ± 2.275 | -2.02 ± 2.062 |
| Change from Baseline at Week 8 | -4.23 ± 2.437 | -2.20 ± 2.353 |
| Change from Baseline at Week 12 | -4.41 ± 2.315 | -2.51 ± 2.350 |
| Change from Baseline at Week 16 | -4.24 ± 2.279 | -2.47 ± 2.226 |
| Change from Baseline at Week 24 | -4.23 ± 2.400 | -4.85 ± 2.323 |
| Change from Baseline at Week 32 | -4.41 ± 2.163 | -5.01 ± 2.095 |
ITCH4 response was defined as a ≥4-point improvement in CHE-related Itch Numerical Rating Scale (NRS) score from Baseline. The CHE-related Itch NRS is a once-per-24 hours ("daily") participant-reported measure of the worst itch severity of their CHE assessed using an 11-point scale (0=no itch to 10=worst imaginable itch).
| days | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Time to ≥4-point Improvement From Baseline in CHE-related Itch NRS Score | 15.0 (12.0 to 18.0) | 29.0 (17.0 to 73.0) |
The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Baseline | 6.14 ± 2.164 | 6.06 ± 1.754 |
| Change from Baseline at Week 2 | -2.86 ± 2.433 | -1.27 ± 1.671 |
| Change from Baseline at Week 4 | -3.82 ± 2.435 | -1.83 ± 1.929 |
| Change from Baseline at Week 8 | -4.15 ± 2.625 | -1.95 ± 2.118 |
| Change from Baseline at Week 12 | -4.25 ± 2.415 | -2.21 ± 2.206 |
| Change from Baseline at Week 16 | -4.23 ± 2.627 | -2.32 ± 2.036 |
| Change from Baseline at Week 24 | -4.25 ± 2.584 | -4.47 ± 2.261 |
| Change from Baseline at Week 32 | -4.37 ± 2.524 | -4.61 ± 2.112 |
The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).
| percentage of participants | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Week 2 | 59.0 (47.693 to 69.715) | 34.1 (24.027 to 45.449) |
| Week 4 | 76.7 (66.394 to 85.179) | 47.5 (36.213 to 58.977) |
| Week 8 | 74.4 (63.555 to 83.396) | 52.0 (40.151 to 63.686) |
| Week 12 | 84.0 (73.719 to 91.450) | 53.5 (41.287 to 65.452) |
| Week 16 | 81.9 (71.106 to 90.021) | 58.6 (46.166 to 70.228) |
| Week 24 | 83.3 (72.133 to 91.375) | 90.2 (79.810 to 96.304) |
| Week 32 | 86.8 (76.356 to 93.765) | 88.3 (77.428 to 95.179) |
The CHE-related Pain NRS is a once-per-24 hours ("daily") participant-reported measure of the worst pain severity of their CHE assessed using an 11-point scale (0=no pain to 10=worst imaginable pain).
| days | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Time to ≥2-point Improvement From Baseline in CHE-related Skin Pain NRS Score | 5.0 (4.0 to 7.0) | 8.0 (5.0 to 12.0) |
The HECSI divides the hand into 5 areas for assessment (fingertips, fingers \[except the tips\], palms, back of hands, and wrists). Each of the 5 areas of the hand are assessed separately for erythema, induration/papulation, vesicles, fissuring, scaling, and edema using the following scale: 0, no skin changes; 1, mild disease; 2, moderate disease; and 3, severe disease. To determine the HECSI score, the affected area for each location (total of both hands) is given a score from 0 to 4 (0, 0%; 1, 1%-25%; 2, 26%-50%; 3, 51%-75%; and 4, 76%-100%) based on the extent of clinical symptoms. Finally, the score given for the extent at each location is multiplied by the total sum of the intensity of each clinical feature to calculate the total HECSI score, varying from 0 to a maximum severity score of 360 points. Percentage change was calculated as the (\[post-Baseline value minus the Baseline value\]/\[Baseline value\]) \* 100.
| percentage change | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Week 2 | -54.93 ± 34.148 | -16.68 ± 50.066 |
| Week 4 | -69.58 ± 37.852 | -26.00 ± 58.790 |
| Week 8 | -77.25 ± 29.583 | -33.81 ± 62.468 |
| Week 12 | -78.65 ± 37.390 | -41.00 ± 50.605 |
| Week 16 | -84.88 ± 22.971 | -37.61 ± 54.760 |
The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement of CHE. Participants were asked to select 1 response from the response options that best described the overall change in their CHE since they started study treatment: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse, and 7, very much worse.
| scores on a scale | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Week 2 | 1.85 ± 0.824 | 3.21 ± 1.309 |
| Week 4 | 1.74 ± 0.897 | 3.09 ± 1.288 |
| Week 8 | 1.64 ± 0.784 | 3.04 ± 1.344 |
| Week 12 | 1.60 ± 0.851 | 3.04 ± 1.399 |
| Week 16 | 1.61 ± 0.893 | 3.00 ± 1.308 |
| Week 24 | 1.61 ± 0.750 | 1.73 ± 0.931 |
| Week 32 | 1.57 ± 0.932 | 1.67 ± 0.877 |
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. The questionnaire was analyzed under 6 subscales as follows: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); and treatment (Question 10). Scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0 (Question 7: "Prevented work or studying" = Yes = 3). The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.
| scores on a scale | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Baseline | 13.17 ± 6.277 | 11.84 ± 5.896 |
| Change from Baseline at Week 2 | -7.95 ± 5.046 | -3.62 ± 4.065 |
| Change from Baseline at Week 4 | -8.68 ± 5.517 | -4.78 ± 5.116 |
| Change from Baseline at Week 8 | -9.11 ± 5.837 | -5.32 ± 4.977 |
| Change from Baseline at Week 12 | -9.38 ± 5.905 | -5.88 ± 5.964 |
| Change from Baseline at Week 16 | -9.62 ± 6.055 | -5.36 ± 5.441 |
| Change from Baseline at Week 24 | -8.97 ± 6.457 | -8.71 ± 5.517 |
| Change from Baseline at Week 32 | -9.71 ± 5.675 | -9.34 ± 5.550 |
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score).
| Participants | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Mobility; Baseline, Level 1 | 70 | 73 |
| Mobility; Baseline, Level 2 | 14 | 8 |
| Mobility; Baseline, Level 3 | 5 | 6 |
| Mobility; Baseline, Level 4 | 0 | 1 |
| Mobility; Baseline, Level 5 | 0 | 2 |
| Mobility; Week 2, Level 1 | 74 | 70 |
| Mobility; Week 2, Level 2 | 4 | 9 |
| Mobility; Week 2, Level 3 | 4 | 4 |
| Mobility; Week 2, Level 4 | 2 | 1 |
| Mobility; Week 2, Level 5 | 2 | 0 |
| Mobility; Week 4, Level 1 | 69 | 68 |
| Mobility; Week 4, Level 2 | 13 | 9 |
| Mobility; Week 4, Level 3 | 4 | 3 |
| Mobility; Week 4, Level 4 | 0 | 2 |
| Mobility; Week 4, Level 5 | 0 | 0 |
| Mobility; Week 8, Level 1 | 71 | 70 |
| Mobility; Week 8, Level 2 | 14 | 5 |
| Mobility; Week 8, Level 3 | 0 | 2 |
| Mobility; Week 8, Level 4 | 0 | 1 |
| Mobility; Week 8, Level 5 | 0 | 0 |
| Mobility; Week 12, Level 1 | 67 | 63 |
| Mobility; Week 12, Level 2 | 7 | 9 |
| Mobility; Week 12, Level 3 | 5 | 2 |
| Mobility; Week 12, Level 4 | 1 | 1 |
| Mobility; Week 12, Level 5 | 0 | 0 |
| Mobility; Week 16, Level 1 | 69 | 64 |
| Mobility; Week 16, Level 2 | 7 | 9 |
| Mobility; Week 16, Level 3 | 4 | 2 |
| Mobility; Week 16, Level 4 | 0 | 2 |
| Mobility; Week 16, Level 5 | 0 | 0 |
| Mobility; Week 24, Level 1 | 65 | 60 |
| Mobility; Week 24, Level 2 | 6 | 8 |
| Mobility; Week 24, Level 3 | 4 | 2 |
| Mobility; Week 24, Level 4 | 1 | 0 |
| Mobility; Week 24, Level 5 | 0 | 0 |
| Mobility; Week 32, Level 1 | 61 | 55 |
| Mobility; Week 32, Level 2 | 5 | 7 |
| Mobility; Week 32, Level 3 | 3 | 4 |
| Mobility; Week 32, Level 4 | 0 | 1 |
| Mobility; Week 32, Level 5 | 0 | 0 |
| Self-care; Baseline, Level 1 | 55 | 61 |
| Self-care; Baseline, Level 2 | 24 | 21 |
| Self-care; Baseline, Level 3 | 5 | 6 |
| Self-care; Baseline, Level 4 | 5 | 2 |
| Self-care; Baseline, Level 5 | 0 | 0 |
| Self-care; Week 2, Level 1 | 73 | 64 |
| Self-care; Week 2, Level 2 | 10 | 13 |
| Self-care; Week 2, Level 3 | 3 | 5 |
| Self-care; Week 2, Level 4 | 0 | 1 |
| Self-care; Week 2, Level 5 | 0 | 1 |
| Self-care; Week 4, Level 1 | 69 | 57 |
| Self-care; Week 4, Level 2 | 14 | 19 |
| Self-care; Week 4, Level 3 | 3 | 5 |
| Self-care; Week 4, Level 4 | 0 | 1 |
| Self-care; Week 4, Level 5 | 0 | 0 |
| Self-care; Week 8, Level 1 | 76 | 57 |
| Self-care; Week 8, Level 2 | 6 | 15 |
| Self-care; Week 8, Level 3 | 3 | 6 |
| Self-care; Week 8, Level 4 | 0 | 0 |
| Self-care; Week 8, Level 5 | 0 | 0 |
| Self-care; Week 12, Level 1 | 72 | 61 |
| Self-care; Week 12, Level 2 | 8 | 10 |
| Self-care; Week 12, Level 3 | 0 | 4 |
| Self-care; Week 12, Level 4 | 0 | 0 |
| Self-care; Week 12, Level 5 | 0 | 0 |
| Self-care; Week 16, Level 1 | 72 | 59 |
| Self-care; Week 16, Level 2 | 8 | 16 |
| Self-care; Week 16, Level 3 | 0 | 2 |
| Self-care; Week 16, Level 4 | 0 | 0 |
| Self-care; Week 16, Level 5 | 0 | 0 |
| Self-care; Week 24, Level 1 | 70 | 64 |
| Self-care; Week 24, Level 2 | 4 | 4 |
| Self-care; Week 24, Level 3 | 1 | 2 |
| Self-care; Week 24, Level 4 | 1 | 0 |
| Self-care; Week 24, Level 5 | 0 | 0 |
| Self-care; Week 32, Level 1 | 64 | 62 |
| Self-care; Week 32, Level 2 | 3 | 5 |
| Self-care; Week 32, Level 3 | 2 | 0 |
| Self-care; Week 32, Level 4 | 0 | 0 |
| Self-care; Week 32, Level 5 | 0 | 0 |
| Usual activities; Baseline, Level 1 | 25 | 38 |
| Usual activities; Baseline, Level 2 | 39 | 28 |
| Usual activities; Baseline, Level 3 | 16 | 18 |
| Usual activities; Baseline, Level 4 | 8 | 5 |
| Usual activities; Baseline, Level 5 | 1 | 1 |
| Usual activities; Week 2, Level 1 | 51 | 37 |
| Usual activities; Week 2, Level 2 | 27 | 32 |
| Usual activities; Week 2, Level 3 | 6 | 11 |
| Usual activities; Week 2, Level 4 | 2 | 4 |
| Usual activities; Week 2, Level 5 | 0 | 0 |
| Usual activities; Week 4, Level 1 | 53 | 42 |
| Usual activities; Week 4, Level 2 | 27 | 24 |
| Usual activities; Week 4, Level 3 | 6 | 14 |
| Usual activities; Week 4, Level 4 | 0 | 2 |
| Usual activities; Week 4, Level 5 | 0 | 0 |
| Usual activities; Week 8, Level 1 | 65 | 47 |
| Usual activities; Week 8, Level 2 | 18 | 22 |
| Usual activities; Week 8, Level 3 | 2 | 6 |
| Usual activities; Week 8, Level 4 | 0 | 3 |
| Usual activities; Week 8, Level 5 | 0 | 0 |
| Usual activities; Week 12, Level 1 | 60 | 45 |
| Usual activities; Week 12, Level 2 | 17 | 26 |
| Usual activities; Week 12, Level 3 | 3 | 1 |
| Usual activities; Week 12, Level 4 | 0 | 3 |
| Usual activities; Week 12, Level 5 | 0 | 0 |
| Usual activities; Week 16, Level 1 | 61 | 42 |
| Usual activities; Week 16, Level 2 | 16 | 25 |
| Usual activities; Week 16, Level 3 | 3 | 8 |
| Usual activities; Week 16, Level 4 | 0 | 1 |
| Usual activities; Week 16, Level 5 | 0 | 1 |
| Usual activities; Week 24, Level 1 | 55 | 54 |
| Usual activities; Week 24, Level 2 | 18 | 13 |
| Usual activities; Week 24, Level 3 | 2 | 3 |
| Usual activities; Week 24, Level 4 | 1 | 0 |
| Usual activities; Week 24, Level 5 | 0 | 0 |
| Usual activities; Week 32, Level 1 | 57 | 61 |
| Usual activities; Week 32, Level 2 | 8 | 4 |
| Usual activities; Week 32, Level 3 | 4 | 2 |
| Usual activities; Week 32, Level 4 | 0 | 0 |
| Usual activities; Week 32, Level 5 | 0 | 0 |
| Pain/discomfort; Baseline, Level 1 | 3 | 5 |
| Pain/discomfort; Baseline, Level 2 | 28 | 28 |
| Pain/discomfort; Baseline, Level 3 | 37 | 36 |
| Pain/discomfort; Baseline, Level 4 | 20 | 19 |
| Pain/discomfort; Baseline, Level 5 | 1 | 2 |
| Pain/discomfort; Week 2, Level 1 | 33 | 17 |
| Pain/discomfort; Week 2, Level 2 | 37 | 35 |
| Pain/discomfort; Week 2, Level 3 | 14 | 20 |
| Pain/discomfort; Week 2, Level 4 | 2 | 11 |
| Pain/discomfort; Week 2, Level 5 | 0 | 1 |
| Pain/discomfort; Week 4, Level 1 | 37 | 15 |
| Pain/discomfort; Week 4, Level 2 | 38 | 38 |
| Pain/discomfort; Week 4, Level 3 | 9 | 25 |
| Pain/discomfort; Week 4, Level 4 | 2 | 2 |
| Pain/discomfort; Week 4, Level 5 | 0 | 2 |
| Pain/discomfort; Week 8, Level 1 | 46 | 22 |
| Pain/discomfort; Week 8, Level 2 | 29 | 36 |
| Pain/discomfort; Week 8, Level 3 | 10 | 13 |
| Pain/discomfort; Week 8, Level 4 | 0 | 7 |
| Pain/discomfort; Week 8, Level 5 | 0 | 0 |
| Pain/discomfort; Week 12, Level 1 | 40 | 20 |
| Pain/discomfort; Week 12, Level 2 | 30 | 37 |
| Pain/discomfort; Week 12, Level 3 | 9 | 16 |
| Pain/discomfort; Week 12, Level 4 | 1 | 1 |
| Pain/discomfort; Week 12, Level 5 | 0 | 1 |
| Pain/discomfort; Week 16, Level 1 | 42 | 20 |
| Pain/discomfort; Week 16, Level 2 | 28 | 38 |
| Pain/discomfort; Week 16, Level 3 | 6 | 14 |
| Pain/discomfort; Week 16, Level 4 | 4 | 4 |
| Pain/discomfort; Week 16, Level 5 | 0 | 1 |
| Pain/discomfort; Week 24, Level 1 | 42 | 40 |
| Pain/discomfort; Week 24, Level 2 | 26 | 22 |
| Pain/discomfort; Week 24, Level 3 | 7 | 7 |
| Pain/discomfort; Week 24, Level 4 | 0 | 1 |
| Pain/discomfort; Week 24, Level 5 | 1 | 0 |
| Pain/discomfort; Week 32, Level 1 | 35 | 39 |
| Pain/discomfort; Week 32, Level 2 | 27 | 22 |
| Pain/discomfort; Week 32, Level 3 | 7 | 5 |
| Pain/discomfort; Week 32, Level 4 | 0 | 1 |
| Pain/discomfort; Week 32, Level 5 | 0 | 0 |
| Anxiety/depression; Baseline, Level 1 | 39 | 41 |
| Anxiety/depression; Baseline, Level 2 | 28 | 28 |
| Anxiety/depression; Baseline, Level 3 | 16 | 11 |
| Anxiety/depression; Baseline, Level 4 | 5 | 9 |
| Anxiety/depression; Baseline, Level 5 | 1 | 1 |
| Anxiety/depression; Week 2, Level 1 | 56 | 43 |
| Anxiety/depression; Week 2, Level 2 | 22 | 29 |
| Anxiety/depression; Week 2, Level 3 | 6 | 8 |
| Anxiety/depression; Week 2, Level 4 | 2 | 3 |
| Anxiety/depression; Week 2, Level 5 | 0 | 1 |
| Anxiety/depression; Week 4, Level 1 | 53 | 46 |
| Anxiety/depression; Week 4, Level 2 | 24 | 24 |
| Anxiety/depression; Week 4, Level 3 | 7 | 6 |
| Anxiety/depression; Week 4, Level 4 | 2 | 5 |
| Anxiety/depression; Week 4, Level 5 | 0 | 1 |
| Anxiety/depression; Week 8, Level 1 | 57 | 46 |
| Anxiety/depression; Week 8, Level 2 | 23 | 24 |
| Anxiety/depression; Week 8, Level 3 | 3 | 5 |
| Anxiety/depression; Week 8, Level 4 | 1 | 3 |
| Anxiety/depression; Week 8, Level 5 | 1 | 0 |
| Anxiety/depression; Week 12, Level 1 | 58 | 46 |
| Anxiety/depression; Week 12, Level 2 | 15 | 19 |
| Anxiety/depression; Week 12, Level 3 | 5 | 7 |
| Anxiety/depression; Week 12, Level 4 | 1 | 2 |
| Anxiety/depression; Week 12, Level 5 | 1 | 1 |
| Anxiety/depression; Week 16, Level 1 | 54 | 46 |
| Anxiety/depression; Week 16, Level 2 | 19 | 23 |
| Anxiety/depression; Week 16, Level 3 | 4 | 5 |
| Anxiety/depression; Week 16, Level 4 | 3 | 2 |
| Anxiety/depression; Week 16, Level 5 | 0 | 1 |
| Anxiety/depression; Week 24, Level 1 | 54 | 50 |
| Anxiety/depression; Week 24, Level 2 | 17 | 15 |
| Anxiety/depression; Week 24, Level 3 | 3 | 3 |
| Anxiety/depression; Week 24, Level 4 | 1 | 2 |
| Anxiety/depression; Week 24, Level 5 | 1 | 0 |
| Anxiety/depression; Week 32, Level 1 | 44 | 54 |
| Anxiety/depression; Week 32, Level 2 | 20 | 11 |
| Anxiety/depression; Week 32, Level 3 | 3 | 2 |
| Anxiety/depression; Week 32, Level 4 | 0 | 0 |
| Anxiety/depression; Week 32, Level 5 | 2 | 0 |
The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome. The EQ-5D-5L questionnaire consists of the following 2 sections: the EQ-5D descriptive system and the EQ Visual Analog Scale (VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: Level 1 = no problems; Level 2 = slight problems; Level 3 = moderate problems; Level 4 = severe problems; and Level 5 = extreme problems. The EQ VAS records the participant's self-rated health on a vertical VAS (0-100), where the endpoints are labeled "the best health you can imagine" (100 score) and "the worst health you can imagine" (0 score). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Baseline | 74.21 ± 18.373 | 73.93 ± 19.255 |
| Change from Baseline at Week 2 | 8.85 ± 18.544 | 4.05 ± 13.191 |
| Change from Baseline at Week 4 | 10.73 ± 19.904 | 5.38 ± 15.042 |
| Change from Baseline at Week 8 | 10.75 ± 19.292 | 6.92 ± 13.006 |
| Change from Baseline at Week 12 | 10.82 ± 20.557 | 8.80 ± 13.343 |
| Change from Baseline at Week 16 | 10.97 ± 20.567 | 7.67 ± 14.160 |
| Change from Baseline at Week 24 | 12.22 ± 21.223 | 10.00 ± 12.444 |
| Change from Baseline at Week 32 | 12.34 ± 21.430 | 11.95 ± 14.807 |
The QOLHEQ is a validated disease-specific instrument to assess disease-specific health-related quality of life in participants suffering from CHE over the past 7 days. It consists of 30 items that are summarized according to impairments for 4 subscales: symptoms, emotions, limitations in functioning, and treatment and prevention. Each item is scored on a scale of never, rarely, sometimes, often, and all the time. The overall score is calculated by summing all items and ranges from 0 to 117. Higher scores indicate a greater impact on quality of life. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Baseline | 75.19 ± 23.864 | 66.52 ± 23.224 |
| Change from Baseline at Week 2 | -43.16 ± 24.337 | -21.98 ± 18.408 |
| Change from Baseline at Week 4 | -50.22 ± 23.579 | -25.10 ± 21.021 |
| Change from Baseline at Week 8 | -53.69 ± 25.377 | -28.44 ± 22.570 |
| Change from Baseline at Week 12 | -55.00 ± 24.109 | -28.95 ± 24.322 |
| Change from Baseline at Week 16 | -55.76 ± 26.741 | -29.56 ± 25.060 |
| Change from Baseline at Week 24 | -54.97 ± 25.757 | -46.60 ± 24.862 |
| Change from Baseline at Week 32 | -55.59 ± 23.885 | -50.04 ± 24.931 |
| Change from Baseline at Safety Follow-up | -48.07 ± 26.886 | -40.67 ± 27.454 |
The WPAI-ChHD questionnaire is a patient-reported quantitative assessment of the amount of absenteeism (measured as percentage of work time missed \[PWTM\] due to CHE), presentism, and daily activity impairment (percentage of impairment while working \[PIWW\] due to CHE, percentage of overall work impairment \[POWI\] due to CHE, percentage of activity impairment \[PAI\] due to CHE) attributable to a specific health problem. The WPAI-ChHD is a 6-item questionnaire used to assess the impact of chronic hand dermatitis (ChHD, the same as CHE in this context) on job performance and productivity in the last 7 days. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Scores range from 0% (no impairment) to 100% (complete impairment). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| percentage | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| PWTM, Baseline | 5.68 ± 16.541 | 2.32 ± 7.736 |
| PWTM, Change from Baseline at Week 2 | -4.90 ± 12.817 | -0.90 ± 5.858 |
| PWTM, Change from Baseline at Week 4 | -3.15 ± 16.734 | 0.82 ± 11.469 |
| PWTM, Change from Baseline at Week 8 | -3.92 ± 19.340 | 0.03 ± 11.714 |
| PWTM, Change from Baseline at Week 12 | -0.72 ± 14.356 | -1.40 ± 9.591 |
| PWTM, Change from Baseline at Week 16 | -0.57 ± 22.398 | 0.06 ± 12.294 |
| PWTM, Change from Baseline at Week 24 | -3.09 ± 12.916 | -0.36 ± 13.845 |
| PWTM, Change from Baseline at Week 32 | -0.80 ± 16.359 | -0.83 ± 15.108 |
| PWTM, Change from Baseline at Safety Follow-up | -0.23 ± 9.681 | -0.67 ± 14.285 |
| PIWW, Baseline | 46.52 ± 28.171 | 38.82 ± 26.176 |
| PIWW, Change from Baseline at Week 2 | -26.56 ± 26.888 | -12.22 ± 21.285 |
| PIWW, Change from Baseline at Week 4 | -27.87 ± 28.642 | -13.87 ± 21.375 |
| PIWW, Change from Baseline at Week 8 | -32.22 ± 25.365 | -13.00 ± 22.944 |
| PIWW, Change from Baseline at Week 12 | -32.81 ± 27.500 | -11.72 ± 23.998 |
| PIWW, Change from Baseline at Week 16 | -35.44 ± 28.162 | -14.33 ± 20.031 |
| PIWW, Change from Baseline at Week 24 | -32.96 ± 27.584 | -28.52 ± 24.984 |
| PIWW, Change from Baseline at Week 32 | -35.51 ± 26.775 | -30.21 ± 24.796 |
| PIWW, Change from Baseline at Safety Follow-up | -30.20 ± 30.672 | -21.67 ± 23.730 |
| POWI, Baseline | 47.82 ± 28.060 | 40.02 ± 26.651 |
| POWI, Change from Baseline at Week 2 | -27.50 ± 26.315 | -10.85 ± 20.548 |
| POWI, Change from Baseline at Week 4 | -25.78 ± 28.135 | -11.08 ± 22.539 |
| POWI, Change from Baseline at Week 8 | -32.66 ± 25.633 | -10.82 ± 21.500 |
| POWI, Change from Baseline at Week 12 | -32.55 ± 29.872 | -11.99 ± 25.552 |
| POWI, Change from Baseline at Week 16 | -33.67 ± 30.196 | -14.10 ± 21.897 |
| POWI, Change from Baseline at Week 24 | -33.95 ± 29.526 | -28.35 ± 29.678 |
| POWI, Change from Baseline at Week 32 | -34.73 ± 28.130 | -29.59 ± 29.227 |
| POWI, Change from Baseline at Safety Follow-up | -29.88 ± 32.391 | -21.20 ± 26.726 |
| PAI, Baseline | 56.40 ± 26.079 | 49.45 ± 24.466 |
| PAI, Change from Baseline at Week 2 | -30.37 ± 26.667 | -11.43 ± 21.236 |
| PAI, Change from Baseline at Week 4 | -34.81 ± 26.651 | -16.71 ± 22.611 |
| PAI, Change from Baseline at Week 8 | -36.25 ± 26.259 | -17.18 ± 24.169 |
| PAI, Change from Baseline at Week 12 | -39.21 ± 26.671 | -20.13 ± 27.680 |
| PAI, Change from Baseline at Week 16 | -41.07 ± 27.439 | -18.70 ± 22.381 |
| PAI, Change from Baseline at Week 24 | -38.47 ± 27.304 | -35.71 ± 26.842 |
| PAI, Change from Baseline at Week 32 | -39.12 ± 25.553 | -38.36 ± 25.382 |
| PAI, Change from Baseline at Safety Follow-up | -32.06 ± 27.782 | -26.27 ± 28.542 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.
| Participants | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) in the DBVC Period | 36 | 29 |
A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With Any ≥Grade 3 TEAE in the DBVC Period | 2 | 1 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up.
| Participants | Open-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID | OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Number of Participants With Any TEAE in the OLE Period | 10 | 25 |
A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up. The severity of AEs was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 using Grades 1 through 5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Open-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID | OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Number of Participants With Any ≥Grade 3 TEAE in the OLE Period | 1 | 1 |
The investigator determined whether a change was clinically meaningful.
| Participants | Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID | DBVC Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the DBVC Period | 0 | 0 |
The investigator determined whether a change was clinically meaningful.
| Participants | Open-label Extension (OLE) Period: Ruxolitinib 1.5% Cream BID | OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Number of Participants With Clinically Meaningful Changes or Trends in Laboratory (Hematology and Serum Chemistry) Parameters or Vital Signs in the OLE Period | 0 | 0 |
Collected over up to Week 36. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Cream BID | 0/92 (0%) | 1/92 (1.1%) | 9/92 (9.8%) |
| Ruxolitinib 1.5% Cream BID | 1/171 (0.6%) | 5/171 (2.9%) | 10/171 (5.8%) |
| Event | Vehicle Cream BID | Ruxolitinib 1.5% Cream BID |
|---|---|---|
| Retinal artery embolismEye disorders | 1/92 | 0/171 |
| Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 1/171 |
| Cardiac arrestCardiac disorders | 0/92 | 1/171 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/92 | 1/171 |
| Prostatic obstructionReproductive system and breast disorders | 0/92 | 1/171 |
| Sinus node dysfunctionCardiac disorders | 0/92 | 1/171 |
| Event | Vehicle Cream BID | Ruxolitinib 1.5% Cream BID |
|---|---|---|
| NasopharyngitisInfections and infestations | 9/92 | 10/171 |
| Age, Continuous(years) | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|
| Mean | 47.8 ± 15.11 | 48.1 ± 15.29 | 48.0 ± 15.16 |
| Sex: Female, Male(Participants) | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|
| Female | 56 | 55 | 111 |
| Male | 38 | 37 | 75 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 87 | 85 | 172 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|
| White/Caucasian | 83 | 85 | 168 |
| Black/African American | 5 | 3 | 8 |
| Asian | 5 | 2 | 7 |
| Not Reported | 0 | 1 | 1 |
| Indian | 1 | 0 | 1 |
| Middle Eastern | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Jul 2023 to primary completion in Jul 2024, 11 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Eczema, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 16. This study's 11 months is below that.
Counting every sponsor, half of 70 studies reached it within 14 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib